Syndax Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Syndax Pharmaceuticals, Inc. on March 15, 2024, reporting events occurring on March 15 and March 18, 2024. The filing addresses significant changes in executive leadership within the company's commercial operations.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes
- Departure: Steve Sabus, the previous Chief Commercial Officer, voluntarily resigned on March 15, 2024, citing personal reasons.
- Appointment: Steven Closter was appointed as the new Chief Commercial Officer, effective March 18, 2024.
- Compensation Structure: Mr. Closter's employment agreement includes an annual base salary of $460,000 and a target annual bonus of 45% of base salary (pro-rated for 2024).
- Equity Awards:
- Stock Option: 150,000 shares with a vesting schedule of 25% after one year and the remainder monthly over 36 months.
- Performance Restricted Stock Units (PRSU): 25,000 units contingent on pre-established performance metrics.
- Sign-on Restricted Stock Units (RSU): 9,000 units vesting over three years.
Outlook, Risks, and Contingencies
The filing details severance provisions in the event of termination without "cause" or for "good reason," including a lump sum payment of nine months' base salary and accelerated vesting of equity awards. In the event of a "change in control" within a specific window, severance increases to 18 months' base salary plus 100% of the target bonus, with full accelerated vesting of all unvested options. The agreement includes a "gross-up" provision to cover excise taxes if payments are deemed "parachute payments" under Section 280G of the Code.
Investor Verification Checklist
- Verify the exact closing price of Syndax common stock on March 18, 2024, to determine the exercise price of the 150,000 stock options granted to Mr. Closter.
- Review the specific performance metrics approved by the Compensation Committee for the 25,000 PRSU award, as these are not detailed in this filing.
- Confirm the pro-rated calculation for Mr. Closter's 2024 target bonus based on his start date.
- Assess the impact of the leadership transition on the company's commercial strategy and pipeline execution.